Personalis’ (PSNL) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Personalis (NASDAQ:PSNL) in a report issued on Thursday,Benzinga reports. They currently have a $7.25 price objective on the stock.

Several other research firms have also recently issued reports on PSNL. BTIG Research boosted their target price on Personalis from $5.50 to $7.00 and gave the company a “buy” rating in a research note on Friday, August 16th. HC Wainwright lifted their price target on Personalis from $7.50 to $9.00 and gave the company a “buy” rating in a research report on Monday, August 19th.

Personalis Trading Up 5.3 %

PSNL opened at $4.55 on Thursday. The business’s 50-day moving average price is $5.13 and its 200-day moving average price is $3.35. The company has a market cap of $241.49 million, a P/E ratio of -2.71 and a beta of 1.94. Personalis has a 12 month low of $0.89 and a 12 month high of $7.20.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.10. The business had revenue of $22.58 million for the quarter, compared to analyst estimates of $19.81 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 72.35%. During the same quarter last year, the firm earned ($0.50) EPS. Equities research analysts forecast that Personalis will post -1.15 earnings per share for the current fiscal year.

Institutional Trading of Personalis

Institutional investors have recently bought and sold shares of the company. IQ EQ FUND MANAGEMENT IRELAND Ltd increased its position in shares of Personalis by 42.5% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company’s stock valued at $81,000 after acquiring an additional 4,504 shares in the last quarter. nVerses Capital LLC bought a new stake in shares of Personalis in the third quarter worth $40,000. International Assets Investment Management LLC increased its position in Personalis by 438.0% during the third quarter. International Assets Investment Management LLC now owns 20,982 shares of the company’s stock valued at $113,000 after acquiring an additional 17,082 shares during the last quarter. Public Employees Retirement System of Ohio bought a new position in Personalis in the first quarter valued at about $29,000. Finally, GSA Capital Partners LLP lifted its stake in shares of Personalis by 6.2% in the 1st quarter. GSA Capital Partners LLP now owns 420,141 shares of the company’s stock worth $626,000 after purchasing an additional 24,498 shares during the period. 61.91% of the stock is owned by hedge funds and other institutional investors.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.